The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.
Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, California.
Mol Cancer Res. 2020 Aug;18(8):1166-1175. doi: 10.1158/1541-7786.MCR-19-1262. Epub 2020 May 20.
Aqueous humor contains tumor-derived cell-free DNA (cfDNA) and can serve as a liquid biopsy for retinoblastoma. We previously associated somatic copy-number alteration (SCNA) 6p gain with a 10-fold increased risk of enucleation. Here we provide a 2-year update to further explore 6p gain as a prognostic biomarker for ocular survival. Patients diagnosed with retinoblastoma from December 2014 to July 2019 from whom aqueous humor was sampled were included. cfDNA was extracted and shallow whole-genome sequencing performed to identify highly recurrent retinoblastoma SCNAs (gain of 1q, 2p, 6p, loss of 13q, 16q). 116 aqueous humor samples from 50 eyes of 46 patients were included: 27 eyes were salvaged, 23 were enucleated. Highly recurrent retinoblastoma SCNAs were found in 66% eyes. 6p gain was the most prevalent SCNA (50% eyes). It was particularly more prevalent in enucleated eyes (73.9%) than in salvaged eyes (29.6%; = 0.004). 6p gain in aqueous humor cfDNA portended nearly 10-fold increased odds of enucleation (OR = 9.87; 95% confidence interval = 1.75-55.65; = 0.009). In the enucleated eyes, 6p gain was associated with aggressive histopathologic features, including necrosis, higher degrees of anaplasia, and focal invasion of ocular structures. With extended follow-up and nearly double the aqueous humor samples, we continue to demonstrate 6p gain as a potential prognostic biomarker for retinoblastoma. IMPLICATIONS: Aqueous humor is a high-yield source of tumor-derived DNA in retinoblastoma eyes. Detection of 6p gain in the aqueous humor allows for targeted, patient-centered therapies based on this molecular prognostic marker. Prospective, multicenter studies with aqueous humor sampled from all eyes at diagnosis are warranted to validate these findings.
房水含有肿瘤游离 DNA(cfDNA),可作为视网膜母细胞瘤的液体活检。我们之前发现 6p 获得与眼球摘除风险增加 10 倍相关。在此,我们提供了 2 年的更新数据,以进一步探索 6p 获得作为眼存活率的预后生物标志物。纳入了 2014 年 12 月至 2019 年 7 月期间被诊断为视网膜母细胞瘤且采集了房水的患者。提取 cfDNA 并进行浅层全基因组测序,以鉴定高复发的视网膜母细胞瘤拷贝数改变(1q、2p、6p 获得,13q、16q 丢失)。共纳入 46 例患者 50 只眼的 116 份房水样本:27 只眼经治疗保留眼球,23 只眼眼球摘除。在 66%的眼中发现了高复发的视网膜母细胞瘤拷贝数改变。6p 获得是最常见的 SCNA(50%的眼)。在眼球摘除眼中尤其更为常见(73.9%),而在保留眼球的眼中则较少见(29.6%;=0.004)。房水中 cfDNA 的 6p 获得预示着眼球摘除的几率几乎增加了 10 倍(OR=9.87;95%置信区间=1.75-55.65;=0.009)。在眼球摘除的眼中,6p 获得与侵袭性组织病理学特征相关,包括坏死、较高的异形程度和眼结构的局灶性侵犯。随着随访时间的延长和房水样本量的增加,我们继续证明 6p 获得是视网膜母细胞瘤的一种潜在预后生物标志物。意义:房水是视网膜母细胞瘤眼中高产量的肿瘤源性 DNA 来源。在房水中检测到 6p 获得,可以基于该分子预后标志物进行靶向、以患者为中心的治疗。需要进行前瞻性、多中心研究,在所有诊断时的眼中采集房水,以验证这些发现。